Observational studyCNS neuroscience & therapeutics2025
Endothelial Glycocalyx in Cerebral Infarction After Endovascular Treatment in Patients With Intracranial Artery Stenosis.
Observational study in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01994161 (Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial
Who cites it
3 citing papers in PubMed.
- Endothelial glycocalyx perturbation in obstructive sleep apnea is associated with repetitive hypoxemia and immunothrombotic endothelial dysfunction.Journal of translational medicine · 2026Article
- Relationship Between Carotid Intima-Media Thickness, Serum Endocan and Hyaluronic Acid Levels in Multiple Sclerosis.Life (Basel, Switzerland) · 2025Article
- Endothelial Glycocalyx in Cerebral Infarction After Endovascular Treatment in Patients With Intracranial Artery Stenosis.CNS neuroscience & therapeutics · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo examine whether plasma glycocalyx levels in patients with severe intracranial arterial stenosis (ICAS) are associated with the prediction of new cerebral infarctions following endovascular treatment.
methods105 patients with ICAS who underwent endovascular treatment were enrolled from September 2020 to June 2021. Plasma glycocalyx components were detected. The condition of the cerebral artery was obtained by high-resolution nuclear magnetic resonance, and risk factors for new cerebral infarction postendovascular treatment in patients with ICAS were analyzed using both univariate and multivariate analyses. The results were presented in a nomogram risk model and evaluated.
resultsThe plasma glycocalyx in patients with ICAS exhibited significant differences compared to healthy individuals (p < 0.05). Multivariate analysis revealed eccentricity (OR = 3.599, 95% CI: 1.168-12.478, p = 0.032) and hyaluronic acid (OR = 5.542, 95% CI: 1.545-23.573, p = 0.013) as risk factors (p < 0.05). The risk model encompassing eccentricity, Remodeling index, blood glucose, hyaluronic acid (HA), and age was presented as a Nomogram, with a C-index of 0.810 (95% CI, 0.729-0.890). To further analyze the risk factors affecting HA plasma concentration, the multivariate analysis showed that fibrinogen and hemoglobin A1c (HbA1C) significantly affected changes in HA.
conclusionWe found that HA is a critical factor in predicting adverse events of cerebral infarction after endovascular treatment in patients with ICAS. Additionally, HbA1C and fibrinogen were identified as factors influencing HA changes.
trial registrationClinicalTrials.gov Identifier: NCT01994161.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.